248 related articles for article (PubMed ID: 30692638)
21. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
22. CDK4-6 inhibitors in breast cancer: current status and future development.
Choo JR; Lee SC
Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1123-1138. PubMed ID: 30360668
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer.
De Luca A; Maiello MR; D'Alessio A; Frezzetti D; Gallo M; Carotenuto M; Normanno N
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):891-900. PubMed ID: 30130984
[TBL] [Abstract][Full Text] [Related]
24. Palbociclib-induced autophagy and senescence in gastric cancer cells.
Valenzuela CA; Vargas L; Martinez V; Bravo S; Brown NE
Exp Cell Res; 2017 Nov; 360(2):390-396. PubMed ID: 28947133
[TBL] [Abstract][Full Text] [Related]
25. The Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Is Tolerated Better than Palbociclib by Advanced Breast Cancer Patients with High Serum Albumin Levels.
Nakatsukasa H; Takahashi M; Takahashi K; Takashima T; Asano Y; Morisaki T; Kashiwagi S; Noda S; Nakamura Y
Biol Pharm Bull; 2022; 45(10):1476-1481. PubMed ID: 36184505
[TBL] [Abstract][Full Text] [Related]
26. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
27. Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells.
Min A; Kim JE; Kim YJ; Lim JM; Kim S; Kim JW; Lee KH; Kim TY; Oh DY; Bang YJ; Im SA
Cancer Lett; 2018 Aug; 430():123-132. PubMed ID: 29729292
[TBL] [Abstract][Full Text] [Related]
28. Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner.
Hsieh FS; Chen YL; Hung MH; Chu PY; Tsai MH; Chen LJ; Hsiao YJ; Shih CT; Chang MJ; Chao TI; Shiau CW; Chen KF
Mol Oncol; 2017 Aug; 11(8):1035-1049. PubMed ID: 28453226
[TBL] [Abstract][Full Text] [Related]
29. [Cell cycle inhibitors in endocrine receptor positive breast cancer].
Sablin MP; Ricci F; Loirat D; Jobard A; Basse C; Romano E; Le Tourneau C; Dieras V
Bull Cancer; 2017 Feb; 104(2):114-122. PubMed ID: 28126188
[TBL] [Abstract][Full Text] [Related]
30. Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry.
Martínez-Chávez A; Rosing H; Hillebrand M; Tibben M; Schinkel AH; Beijnen JH
Anal Bioanal Chem; 2019 Aug; 411(20):5331-5345. PubMed ID: 31209549
[TBL] [Abstract][Full Text] [Related]
31. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.
Yoshida A; Lee EK; Diehl JA
Cancer Res; 2016 May; 76(10):2990-3002. PubMed ID: 26988987
[TBL] [Abstract][Full Text] [Related]
32. Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.
Guan X; LaPak KM; Hennessey RC; Yu CY; Shakya R; Zhang J; Burd CE
Mol Cancer Res; 2017 Mar; 15(3):237-249. PubMed ID: 28039358
[TBL] [Abstract][Full Text] [Related]
33. Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?
El Rassy E; Bakouny Z; Assi T; Kattan J
Future Oncol; 2018 Apr; 14(9):891-895. PubMed ID: 29527939
[TBL] [Abstract][Full Text] [Related]
34. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
35. Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.
Chen F; Liu C; Zhang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2018; 18(9):1241-1251. PubMed ID: 28403773
[TBL] [Abstract][Full Text] [Related]
36. CDK4/6 blockade in breast cancer: current experience and future perspectives.
Zardavas D; Pondé N; Tryfonidis K
Expert Opin Investig Drugs; 2017 Dec; 26(12):1357-1372. PubMed ID: 29027483
[TBL] [Abstract][Full Text] [Related]
37. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D
J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480
[TBL] [Abstract][Full Text] [Related]
38. In vitro study to assess the efficacy of CDK4/6 inhibitor Palbociclib (PD-0332991) for treating canine mammary tumours.
Schoos A; Knab VM; Gabriel C; Tripolt S; Wagner DA; Bauder B; Url A; Fux DA
Vet Comp Oncol; 2019 Dec; 17(4):507-521. PubMed ID: 31207004
[TBL] [Abstract][Full Text] [Related]
39. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
Jansen VM; Bhola NE; Bauer JA; Formisano L; Lee KM; Hutchinson KE; Witkiewicz AK; Moore PD; Estrada MV; Sánchez V; Ericsson PG; Sanders ME; Pohlmann PR; Pishvaian MJ; Riddle DA; Dugger TC; Wei W; Knudsen ES; Arteaga CL
Cancer Res; 2017 May; 77(9):2488-2499. PubMed ID: 28249908
[TBL] [Abstract][Full Text] [Related]
40. Effect of food on the bioavailability of palbociclib.
Ruiz-Garcia A; Plotka A; O'Gorman M; Wang DD
Cancer Chemother Pharmacol; 2017 Mar; 79(3):527-533. PubMed ID: 28204912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]